{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Community+Acquired+Pneumonia%2C+Severe",
    "query": {
      "condition": "Community Acquired Pneumonia, Severe"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T18:18:56.203Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01998399",
      "title": "Ticagrelor in Severe Community Acquired Pneumonia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Community Acquired Pneumonia, Severe"
      ],
      "interventions": [
        {
          "name": "Ticagrelor",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gordon Bernard",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2014-08",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2017-12-11",
      "last_synced_at": "2026-07-23T18:18:56.203Z",
      "location_count": 26,
      "location_summary": "Tucson, Arizona • Colorado Springs, Colorado • Denver, Colorado + 19 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01998399"
    },
    {
      "nct_id": "NCT05722938",
      "title": "Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Community-acquired Pneumonia"
      ],
      "interventions": [
        {
          "name": "Trimodulin",
          "type": "DRUG"
        },
        {
          "name": "Placebo (human albumin 1%)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biotest",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 590,
      "start_date": "2023-09-09",
      "completion_date": "2028-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-07-23T18:18:56.203Z",
      "location_count": 19,
      "location_summary": "Mobile, Alabama • Fresno, California • Sacramento, California + 16 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Lansing",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05722938"
    },
    {
      "nct_id": "NCT01110421",
      "title": "A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumonia, Bacterial",
        "Community-Acquired Infections",
        "Nosocomial Infection",
        "Pneumonia, Ventilator-Associated"
      ],
      "interventions": [
        {
          "name": "Cefepime placebo",
          "type": "DRUG"
        },
        {
          "name": "Cefepime",
          "type": "DRUG"
        },
        {
          "name": "Doripenem",
          "type": "DRUG"
        },
        {
          "name": "Doripenem placebo",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin/clavulanate potassium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "3 Months to 18 Years"
      },
      "enrollment_count": 7,
      "start_date": "2010-12",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2014-07-15",
      "last_synced_at": "2026-07-23T18:18:56.203Z",
      "location_count": 4,
      "location_summary": "Little Rock, Arkansas • Cleveland, Ohio • Toledo, Ohio + 1 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Toledo",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01110421"
    },
    {
      "nct_id": "NCT05254990",
      "title": "Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infectious Pneumonia",
        "Severe COVID-19"
      ],
      "interventions": [
        {
          "name": "Reparixin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dompé Farmaceutici S.p.A",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 414,
      "start_date": "2022-04-27",
      "completion_date": "2024-09-27",
      "has_results": true,
      "last_update_posted_date": "2026-02-24",
      "last_synced_at": "2026-07-23T18:18:56.203Z",
      "location_count": 28,
      "location_summary": "Tucson, Arizona • Orange, California • Denver, Colorado + 24 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05254990"
    },
    {
      "nct_id": "NCT05962606",
      "title": "Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Community-acquired Pneumonia"
      ],
      "interventions": [
        {
          "name": "AON-D21",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aptarion Biotech AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 150,
      "start_date": "2024-02-02",
      "completion_date": "2026-03-16",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-07-23T18:18:56.203Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05962606"
    },
    {
      "nct_id": "NCT05776004",
      "title": "Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pneumonia, Bacterial"
      ],
      "interventions": [
        {
          "name": "CAL02",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eagle Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 276,
      "start_date": "2023-07-22",
      "completion_date": "2026-09-07",
      "has_results": false,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-07-23T18:18:56.203Z",
      "location_count": 7,
      "location_summary": "Fresno, California • Gainesville, Florida • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05776004"
    },
    {
      "nct_id": "NCT04659122",
      "title": "A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19",
        "Undefined"
      ],
      "interventions": [
        {
          "name": "AT-100",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Airway Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2021-08-17",
      "completion_date": "2023-02-23",
      "has_results": false,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-07-23T18:18:56.203Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04659122"
    },
    {
      "nct_id": "NCT00035347",
      "title": "Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Community-Acquired Pneumonia (CAP)"
      ],
      "interventions": [
        {
          "name": "IV azithromycin",
          "type": "DRUG"
        },
        {
          "name": "ceftriaxone",
          "type": "DRUG"
        },
        {
          "name": "oral azithromycin",
          "type": "DRUG"
        },
        {
          "name": "IV levofloxacin",
          "type": "DRUG"
        },
        {
          "name": "oral levofloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 219,
      "start_date": "2001-01",
      "completion_date": "2002-06",
      "has_results": false,
      "last_update_posted_date": "2017-03-10",
      "last_synced_at": "2026-07-23T18:18:56.203Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Long Beach, California • Sylmar, California + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Sylmar",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00035347"
    },
    {
      "nct_id": "NCT00084071",
      "title": "Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumonia"
      ],
      "interventions": [
        {
          "name": "Tifacogin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 2136,
      "start_date": "2004-05",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-07-23T18:18:56.203Z",
      "location_count": 51,
      "location_summary": "Mobile, Alabama • Loma Linda, California • Los Angeles, California + 48 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00084071"
    },
    {
      "nct_id": "NCT01283009",
      "title": "Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Community Acquired Respiratory Disease Syndrome"
      ],
      "interventions": [
        {
          "name": "Inactive Substance",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 584,
      "start_date": "2012-01-09",
      "completion_date": "2016-08-31",
      "has_results": true,
      "last_update_posted_date": "2020-10-08",
      "last_synced_at": "2026-07-23T18:18:56.203Z",
      "location_count": 29,
      "location_summary": "Phoenix, Arizona • Loma Linda, California • Long Beach, California + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01283009"
    }
  ]
}